Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Curanex Pharmaceuticals Inc Common Stock (CURX)
USD0.22
+0.01 (+2.52%)
US NASDAQ Healthcare Biotechnology
Address
2 Jericho Plaza 11753
Jericho, NY, US
Jericho, NY, US
CEO
Jun Liu
Website
curanexpharma.com
IPO
2025-08-26
CIK 2025942 ISIN US23126K1060
Description
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.22
+0.01 (+2.52%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
98.0K
Beta
-2.85
Float Shares
7.53M
Free Float %
26.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.00% | +3.61% | -20.24% | -26.14% | -31.75% | +0.60% | -91.73% | -91.73% | -91.73% | -91.73% | -91.73% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.22
DCF (Unlevered)
0.18
-15.8%
DCF (Levered)
0.18
-15.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Quality scores
Altman Z-Score
14.33
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-1,207.7% Q1'26: -2,100.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-8.1% ★ Q1'26: +2.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.08× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-954.5K
OE per share TTM
-0.03
Owner's Yield
-10.13%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1,356.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
8
Total invested
167.6K
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
8
-3 vs prev Q
New positions
2
Closed positions
5
Increased
4
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 111.1K +92.5K (+495.2%) | 56.8K +50.6K (+820.6%) | 0.39% +0.319 pp | 0.00% +0.000 pp | USD0.55 -7.3% | 3 qtrs — |
| 2 | TWO SIGMA SECURITIES, LLC | 56.7K +56.7K (+100.0%) | 29.0K +29.0K (+100.0%) | 0.20% +0.200 pp | 0.00% +0.003 pp | USD0.51 +0.0% | 3 qtrs — |
| 3 | XTX TOPCO LTD | 51.3K +8.9K (+21.0%) | 26.2K +12.2K (+87.2%) | 0.18% +0.015 pp | 0.00% +0.000 pp | USD0.36 +41.7% | 2 qtrs — |
| 4 | CITADEL ADVISORS LLC | 50.6K -53.7K (-51.5%) | 25.9K -8.6K (-25.0%) | 0.18% -0.231 pp | 0.00% +0.000 pp | USD0.57 -10.5% | 3 qtrs — |
| 5 | TWO SIGMA INVESTMENTS, LP | 20.3K -40.8K (-66.9%) | 10.4K -9.8K (-48.7%) | 0.07% -0.168 pp | 0.00% +0.000 pp | USD0.33 +54.5% | 2 qtrs — |
| 6 | CITIGROUP INC | 19.3K +19.3K (+100.0%) | 9.9K +9.9K (+100.0%) | 0.07% +0.068 pp | 0.00% +0.000 pp | USD0.51 +0.0% | 1 qtrs NEW |
| 7 | JUMP FINANCIAL, LLC | 10.6K -6.9K (-39.5%) | 5.4K -384.0 (-6.6%) | 0.04% -0.031 pp | 0.00% +0.000 pp | USD0.72 -29.2% | 3 qtrs — |
| 8 | UBS GROUP AG | 8.0K -5.0K (-38.5%) | 4.1K -215.0 (-5.0%) | 0.03% -0.023 pp | 0.00% +0.000 pp | USD0.72 -29.2% | 3 qtrs — |
| 9 | JANE STREET GROUP, LLC | — -25.0K (-100.0%) | — -8.3K (-100.0%) | 0.00% -0.098 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 10 | DRW SECURITIES, LLC | — -71.6K (-100.0%) | — -23.7K (-100.0%) | 0.00% -0.281 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 11 | HRT FINANCIAL LP | — -12.4K (-100.0%) | — -4.0K (-100.0%) | 0.00% -0.049 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 12 | BANK OF AMERICA CORP /DE/ | — -34.0 (-100.0%) | — -11.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 13 | RENAISSANCE TECHNOLOGIES LLC | — -59.3K (-100.0%) | — -19.6K (-100.0%) | 0.00% -0.233 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-25 | Zhong Huijuan | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-25 | Zhang Ning | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-25 | Yan Yong | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-25 | Xie Liqin | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-25 | Liu Jun | Director / Officer / 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 7,076,160 | D | ↗ |
| 2025-08-25 | Liu Chang | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 4,870,020 | D | ↗ |
| 2025-08-25 | Jing Dian Ying | Officer / 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 7,076,160 | I | ↗ |
| 2025-08-25 | Hsu Helen Hong | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-25 | Hao Xiaohui | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2011-06-24 | WRIGHT TIMOTHY R | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2011-06-24 | GEORGE MICHAEL W | Director | — | D | Common Stock | 0 | 0.00 | — | 15,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
28.34M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dian Ying Jing | Secretary | — | female |
| Haiyan Yang | Chief Financial Officer & Treasurer | — | female |
| Huijuan Zhong | Chief Science Officer & Director | — | — |
| Jun Liu | Chief Executive Officer, President & Chairman | — | male |
| Liqin Xie | Chief Operating Officer | — | — |
| Ning Zhang | Chief Technology Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CURX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
